Om kinome profiling of cells treated with distinct concentrations of MK-2206 and for different time intervals. 1_30: treatment of 30 min with 1 M of MK-2206, and so forth. Abbreviations ALL: Acute lymphoblastic leukemia; DE: Differentially expressed; FDR: False discovery rate; adjP: FDR adjusted P-value; IC50: Half maximal inhibitory concentration; IPA: Ingenuity pathways analysis; logFC: Log fold alter; MSC: Mesenchymal stem cell; Ser/Thr: Serine/threonine. Competing interests Riet Hilhorst and Monique Mommersteeg are PamGene International B.V. staff. The other authors declare that they’ve no conflict of interests. Authors’ contributions MLK performed all bioinformatics analyses and wrote the manuscript. RH and MM performed kinome profiling experiments. BEWMA and MLK performed inhibition studies. EPB and MS had been involved in collection of cell line information. MLK, AMC, PCWH, RH, and HB designed the study. All authors study and approved the final version from the manuscript. Acknowledgments The authors would prefer to thank N. Duinkerken for the NALM-6 cell line. This study was funded by EuroBoNeT (LSHC-CT-2006-018814), the Dutch Cancer Society (KWF, 2008060), the Netherlands Organization for Overall health Investigation and Development (9200399). Author particulars 1 Department of Pathology, Leiden University Health-related Center, Albinusdreef 2, 2300RC Leiden, The Netherlands. 2Current affiliation: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA. 3Current affiliation: Division of Biostatistics, Harvard School of Public Health, Boston, MA, USA. 4PamGene International BV, `s-Hertogenbosch, The Netherlands. 5Department of Pediatrics, Leiden University Health-related Center, Leiden, The Netherlands. 6Laboratory of Experimental Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy. 7Institute of Pathology, Paderborn/H ter, Germany. Received: 24 April 2013 Accepted: 14 January 2014 Published: 21 January 2014 References 1. Raymond AK, Ayala AG, Knuutila S: Standard osteosarcoma. In Planet Wellness Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by Fletcher CDM, Unni KK, Mertens F. Lyon: IARC Press; 2002:26470.two.three.4.5.6. 7.8. 9.10.11. G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P: Prognostic elements for osteosarcoma on the extremity treated with neoadjuvant chemotherapy – 15-year knowledge in 789 sufferers treated at a single institution. Cancer 2006, 106:1154161. Buddingh EP, Anninga JK, Versteegh MI, Taminiau AH, Egeler RM, van Rijswijk CS, Hogendoorn PCW, Lankester AC, Gelderblom H: Prognostic variables in pulmonary metastasized PRMT5 Inhibitor custom synthesis high-grade osteosarcoma. Pediatr Blood Cancer 2010, 54:21621. Allison DC, Carney SC, p38 MAPK Activator custom synthesis Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR: A meta-analysis of osteosarcoma outcomes in the contemporary medical era. Sarcoma 2012, 2012:704872. Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AHM, Hogendoorn PCW, Egeler RM: Chemotherapeutic adjuvant remedy for osteosarcoma: exactly where do we stand Eur J Cancer 2011, 47:2431445. Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M: Emerging drugs for high-grade osteosarcoma. Professional Opin Emerg Drugs 2010, 15:61534. Cleton-Jansen AM, Buerger H, Hogendoom PCW: Central high-grade osteosarcoma of bone: diagnostic and genetic considerations. Curr Diagn Pathol 2005, 11:39099. Szuhai K, Cleton-Jansen AM, Hogendoorn Computer, Bovee JV: Molecular pathology and its diagnostic us.